Search
Search
Search
Close this search box.

Investors Press Releases

Xybion Digital Inc. Press Releases

Xybion Launches a Rapid COVID-19 Diagnostic Lab Management System: Labwise XD COVAPP

PRINCETON, N.J., August 10, 2021 Xybion Corporation, an innovative global life sciences company providing key software to the most recognized names in COVID-19 vaccination, today announces the release of Labwise XD COVAPP, a software system built for the high volume needs of COVID-19 test laboratories inundated by the worldwide spread of the COVID-19 Delta variant.

COVAPP offers a unified and streamlined approach to COVID-19 test management with:

  • Patient Registration
  • COVID-19 test reports
  • Sample management
  • Test management
  • Inventory management
  • Invoicing
  • Reporting


As the COVID-19 Delta variant continues to rapidly proliferate and reshape daily lives at global scale, Labwise XD COVAPP reshapes laboratory processes with a faster response to COVID-19 test requirements with immediate functionality for all COVID-19 strains. COVAPP provides a streamlined approach to patient data, sample management, reporting, and an automated test results notification system. Implementation of COVAPP allows you to achieve:

  • Automated Test Result notification – Test results are delivered immediately to the patient upon submission of a positive result into COVAPP
  • Increased Throughput – COVAPP eliminates manual processes and automates them
  • Increased Testing Capacity – COVAPP’s streamlined approach to COVID-19 Test Management
  • Greater Compliance – All of COVAPP’s features are built on a low-code, cloud-based system built for compliance and HIPAA
  • Scalability – Rapidly scale your throughput and expand your operations with seamless scalability.


The launch of COVAPP provides all laboratories and testing facilities with a full-scale laboratory information management system, or LIMS that is unified with quality, compliance, electronic lab notebooks, and all of the integral components of successful COVID-19 test management. COVAPP connects with your existing systems or works as a standalone module, allowing existing COVID-19 testing facilities to rapidly scale and enabling new and emerging facilities to start performing tests in only two weeks.

“Diagnostic labs are working tirelessly to meet the increasing and unprecedented demands of COVID-19 testing with limited staff and facilities. The only way to meet greater demand with reduced labor is to automate the most time-consuming COVID-19 test processes. COVAPP answers the needs of diagnostic laboratories by streamlining and automating laboratory processes from sample receipt to reporting results. COVAPP was designed for both the lab scientist and the lab director, providing optimized operational efficiency and increased COVID-19 testing capacity,” says Joseph Kalina, Marketing Manager of Xybion.

To learn more about Labwise XD COVAPP, visit: https://www.xybion.com/digital-lab-management-system/covapp-covid-19-test-management-application/


About Xybion Corporation

Xybion is a leading SaaS company dedicated to providing life sciences and health systems companies with innovative software solutions to accelerate the transformation of today’s inventions into tomorrow’s approved medicines, devices, and diagnostic tests designed to save lives and keep employees safe. Our intelligent cloud platform and software solutions help companies accelerate digital transformation of processes, speed up innovation, optimize operations, reduce compliance risks, and achieve significant cost savings. Xybion is serving over 160 customers in 25 countries including all the top 20 global biopharmaceutical companies.

Xybion’s global scale and expertise brings employees around the world to help companies in life sciences, health systems, research institutions, and governments. We put over 40 years of expertise in action every day to help companies digitally transform their regulated business operations. Our unique solutions focus on employee health and safety, integrated preclinical lab management, early-stage drug discovery, digital lab solutions, regulatory compliance, GRC, quality management, predictive compliance, content management, and systems validation.

Learn more about Xybion at https://www.xybion.com/

Contacts

Media
Joseph Kalina
Xybion Corporation
609-512-5790 x 316
[email protected]

Share Press Release

LinkedIn
Facebook
Twitter
Pinterest
Reddit
WhatsApp
Email

Contact Investor Relations

Investor relations serves prospective investors like you seeking insight about Xybion Digital's operations, strategies, vision, and investment options.

Connect with our investor relations team today.